National Storage Mechanism | Additional information
RNS Number : 5518F
Societe Generale SA
17 November 2020
 

Ap19

 

 

FORM 8.3

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1.       KEY INFORMATION

 

Name of person dealing (Note 1)

Société Générale S.A.

Company dealt in

               Willis Towers Watson plc

Class of relevant security to which the dealings being disclosed relate (Note 2)

US$0.000304635 ordinary shares

Date of dealing

16/11/2020

 

2.         INTERESTS AND SHORT POSITIONS

 

(a)        Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

 

 

Long

Short

Number

(%)

Number

(%)

(1) Relevant securities

434,234

0.34

1,727

0.00

(2) Derivatives (other than options)

1,490

0.00

12,296

0.01

(3) Options and agreements to purchase/sell

0

0.00

0

0.00

Total

*1,140,142

*0.88

14,023

0.01

                               

* Include the holding of 704,418 shares on borrow products

 

               

(b)        Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

 

Class of relevant security:

Long

Short

 

Number

(%)

Number

(%)

(1) Relevant securities

 

 

 

 

(2) Derivatives (other than options)

 

 

 

 

(3) Options and agreements to purchase/sell

 

 

 

 

Total

 

 

 

 

 

 

Ap20

 

 

1.       DEALINGS (Note 4)

 

(a)      Purchases and sales

 

Purchase/sale

Number of relevant securities

Price per unit USD (Note 5)

Purchase

100

210.73

Purchase

5,000

210.61

Purchase

1,497

210.61

Purchase

7

210.33

Purchase

33

210.33

Purchase

60

210.39

Purchase

40

210.39

Purchase

30

210.33

Purchase

30

210.33

Purchase

20

209.43

Purchase

20

209.43

Purchase

20

209.43

Purchase

20

209.43

Purchase

20

209.43

Purchase

40

210.08

Purchase

60

210.08

Purchase

13

210.13

Purchase

100

210.61

Purchase

5

210.34

Purchase

15

210.27

Purchase

45

210.21

Purchase

17

210.14

Purchase

93

210.42

Purchase

7

210.42

Purchase

11

210.43

Purchase

45

210.1

Purchase

22

210.59

Purchase

10

210.24

Purchase

20

210.15

Purchase

8

210.23

Purchase

11

210.84

Purchase

10

210.59

Purchase

9

210.23

Purchase

10

210.26

Purchase

13

209.66

Purchase

45

210.34

Purchase

10

210

Purchase

34

210.23

Purchase

17

210.47

Purchase

8

209.95

Purchase

92

209.95

Purchase

11

210.39

Purchase

100

210.37

Purchase

69

210.39

Purchase

20

210.39

Purchase

78

210

Purchase

117

210

Purchase

448

210

Purchase

1

209.9

Purchase

250

210.04

Purchase

61

210.04

Purchase

124

210.04

Sale

1,809

210.61

Sale

100

209.35

Sale

100

209.36

Sale

50

209.3

Sale

1

209.33

Sale

36

209.31

Sale

100

209.32

Sale

26

209.3

Sale

2,002

210.61

Total Purchases

8,946

 

Total Sales

4,224

 

 

 

(b)      Derivatives transactions (other than options transactions)

 

Product name,

e.g. CFD

Nature of transaction

(Note 6)

Number of relevant securities

(Note 7)

Price per unit USD

(Note 5)

 

 

 

 

 

(c)      Options transactions in respect of existing relevant securities

 

 

(i)       Writing, selling, purchasing or varying

 

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 5)

 

 

 

 

 

 

 

 

 

(ii)      Exercising

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 5)

 

 

 

 

(d)      Other dealings (including transactions in respect of new securities) (Note 4)

 

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)

 

 

 

 

Ap21

2.       OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

 

 

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the 

voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition 

or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

 

 

 

 

 

 

 

 

 

 

Is a Supplemental Form 8 attached? (Note 9)                                            No

 

Date of disclosure

17/11/2020

Contact name

Société Générale - Disclosure team

Telephone number

+33 1 42 14 92 74

If a connected EFM, name of offeree/offeror with which connected

 

If a connected EFM, state nature of connection (Note 10)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ISEDDLBFBFLBFBF